[{"address1": "Wagistrasse 14", "city": "Schlieren", "zip": "8952", "country": "Switzerland", "phone": "41 44 755 77 00", "fax": "41 44 755 77 07", "website": "https://www.molecularpartners.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.", "fullTimeEmployees": 167, "maxAge": 86400, "priceHint": 2, "previousClose": 11.01, "open": 9.92, "dayLow": 9.3, "dayHigh": 10.2, "regularMarketPreviousClose": 11.01, "regularMarketOpen": 9.92, "regularMarketDayLow": 9.3, "regularMarketDayHigh": 10.2, "beta": 0.778, "forwardPE": -6.1538467, "volume": 86497, "regularMarketVolume": 86497, "averageVolume": 24679, "averageVolume10days": 115360, "averageDailyVolume10Day": 115360, "bid": 9.69, "bidSize": 100, "marketCap": 334946880, "fiftyTwoWeekLow": 3.32, "fiftyTwoWeekHigh": 12.7, "priceToSalesTrailing12Months": 49.798824, "fiftyDayAverage": 4.4118, "twoHundredDayAverage": 4.359955, "currency": "USD", "enterpriseValue": 144759456, "floatShares": 17151321, "sharesOutstanding": 33182100, "sharesShort": 49223, "sharesShortPriorMonth": 56355, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.0015, "heldPercentInstitutions": 0.028800001, "shortRatio": 15.95, "impliedSharesOutstanding": 34890300, "bookValue": 5.128, "priceToBook": 1.8720751, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -58531000, "trailingEps": -2.01, "forwardEps": -1.56, "enterpriseToRevenue": 21.522, "enterpriseToEbitda": -2.375, "52WeekChange": 0.56606853, "SandP52WeekChange": 0.26238096, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "MOLN", "underlyingSymbol": "MOLN", "shortName": "Molecular Partners AG", "longName": "Molecular Partners AG", "firstTradeDateEpochUtc": 1623850200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "3b1227e2-09aa-3330-8282-b0e2c7493dad", "messageBoardId": "finmb_32677064", "gmtOffSetMilliseconds": -14400000, "currentPrice": 9.6, "targetHighPrice": 16.82, "targetLowPrice": 4.06, "targetMeanPrice": 8.94, "targetMedianPrice": 5.94, "recommendationMean": 2.7, "recommendationKey": "hold", "numberOfAnalystOpinions": 3, "totalCash": 174132992, "totalCashPerShare": 5.298, "ebitda": -60955000, "totalDebt": 3351000, "quickRatio": 14.441, "currentRatio": 14.676, "totalRevenue": 6726000, "debtToEquity": 1.988, "revenuePerShare": 0.205, "returnOnAssets": -0.17982, "returnOnEquity": -0.29962, "freeCashflow": -36798752, "operatingCashflow": -59510000, "revenueGrowth": -0.102, "operatingMargins": -5.79182, "financialCurrency": "CHF", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]